Grant of Interim Extension of the Term of U.S. Patent No. 5,624,923; Lixivaptan, 59008 [2013-23325]
Download as PDF
<![CDATA[
59008
Federal Register / Vol. 78, No. 186 / Wednesday, September 25, 2013 / Notices
through the Information Collection
Review page at www.reginfo.gov.
Paper copies can be obtained by:
• Email: InformationCollection@
uspto.gov. Include ‘‘0651–0022 copy
request’’ in the subject line of the
message.
• Mail: Susan K. Fawcett, Records
Officer, Office of the Chief Information
Officer, United States Patent and
Trademark Office, P.O. Box 1450,
Alexandria, VA 22313–1450.
Written comments and
recommendations for the proposed
information collection should be sent on
or before October 25, 2013 to Nicholas
A. Fraser, OMB Desk Officer, via email
to Nicholas_A_Fraser@omb.eop.gov or
by fax to 202–395–5167, marked to the
attention of Nicholas A. Fraser.
Dated: September 20, 2013.
Susan K. Fawcett,
Records Officer, USPTO, Office of the Chief
Information Officer.
[FR Doc. 2013–23294 Filed 9–24–13; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
United States Patent and Trademark
Office
[Docket No.: PTO–P–2013–0048]
Grant of Interim Extension of the Term
of U.S. Patent No. 5,624,923; Lixivaptan
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term
Extension.
AGENCY:
extend beyond the expiration date of the
patent.
On July 11, 2013, Cardiokine
Biopharma, LLC timely filed an
application under 35 U.S.C. 156(d)(5)
for an interim extension of the term of
U.S. Patent No. 5,624,923. The patent
claims the human drug product
lixivaptan. The application indicates
that a New Drug Application, 203,009,
for the drug product lixivaptan was filed
on December 29, 2011, and is currently
undergoing regulatory review before the
Food and Drug Administration for
permission to market or use the product
commercially.
Review of the application indicates
that, except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Because the
regulatory review period has continued
beyond the original expiration date of
the patent, July 29, 2013, interim
extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
5,624,923 is granted for a period of one
year from the original expiration date of
the patent.
Grant of Interim Extension of the Term
of U.S. Patent No. 5,454,779;
ResQPump®/ResQPOD® ITD
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to her attention at
(571) 273–7755; or by email to
Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On August 21, 2013, the Regents of
the University of California timely filed
an application under 35 U.S.C. 156(d)(5)
for a second interim extension of the
term of U.S. Patent No. 5,454,779. The
patent claims the medical device,
ResQPump® in connection with the
ResQPOD® ITD. The application
indicates that a Premarket Approval
Application, PMA No. P110024, for the
medical device has been filed, and is
currently undergoing regulatory review
before the Food and Drug
Administration for permission to market
or use the product commercially.
Review of the application indicates
that, except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Because it is
apparent that the regulatory review
period will continue beyond the
extended expiration date of the patent,
October 3, 2013, interim extension of
the patent term under 35 U.S.C.
156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
5,454,779 is granted for a period of one
year from the extended expiration date
of the patent.
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term
Extension.
Dated: September 20, 2013.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination
Policy, United States Patent and Trademark
Office.
Dated: September 20, 2013.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination
Policy, United States Patent and Trademark
Office.
[FR Doc. 2013–23325 Filed 9–24–13; 8:45 am]
BILLING CODE 3510–16–P
The United States Patent and
Trademark Office has issued an order
granting interim extension under 35
U.S.C. 156(d)(5) for a one-year interim
extension of the term of U.S. Patent No.
5,624,923.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to her attention at
(571) 273–7755; or by email to
Mary.Till@uspto.gov.
SUMMARY:
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
mstockstill on DSK4VPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
17:20 Sep 24, 2013
Jkt 229001
DEPARTMENT OF COMMERCE
United States Patent and Trademark
Office
[Docket No.: PTO–P–2013–0047]
AGENCY:
The United States Patent and
Trademark Office has issued a second
order granting interim extension under
35 U.S.C. 156(d)(5) for a one-year
interim extension of the term of U.S.
Patent No. 5,454,779.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
SUMMARY:
PO 00000
Frm 00018
Fmt 4703
Sfmt 4703
[FR Doc. 2013–23327 Filed 9–24–13; 8:45 am]
BILLING CODE 3510–16–P
COMMODITY FUTURES TRADING
COMMISSION
Sunshine Act Meeting
10:00 a.m., Friday,
October 18, 2013
TIME AND DATE:
E:\FR\FM\25SEN1.SGM
25SEN1
]]>Agencies
[Federal Register Volume 78, Number 186 (Wednesday, September 25, 2013)]
[Notices]
[Page 59008]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-23325]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
[Docket No.: PTO-P-2013-0048]
Grant of Interim Extension of the Term of U.S. Patent No.
5,624,923; Lixivaptan
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term Extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting interim extension under 35 U.S.C. 156(d)(5) for a one-
year interim extension of the term of U.S. Patent No. 5,624,923.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to one year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On July 11, 2013, Cardiokine Biopharma, LLC timely filed an
application under 35 U.S.C. 156(d)(5) for an interim extension of the
term of U.S. Patent No. 5,624,923. The patent claims the human drug
product lixivaptan. The application indicates that a New Drug
Application, 203,009, for the drug product lixivaptan was filed on
December 29, 2011, and is currently undergoing regulatory review before
the Food and Drug Administration for permission to market or use the
product commercially.
Review of the application indicates that, except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for one year as required by 35
U.S.C. 156(d)(5)(B). Because the regulatory review period has continued
beyond the original expiration date of the patent, July 29, 2013,
interim extension of the patent term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 5,624,923 is granted for a period of one year from the
original expiration date of the patent.
Dated: September 20, 2013.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination Policy, United States Patent
and Trademark Office.
[FR Doc. 2013-23325 Filed 9-24-13; 8:45 am]
BILLING CODE 3510-16-P
